224 related articles for article (PubMed ID: 31300747)
1. Genetic characterization of ABT-199 sensitivity in human AML.
Bisaillon R; Moison C; Thiollier C; Krosl J; Bordeleau ME; Lehnertz B; Lavallée VP; MacRae T; Mayotte N; Labelle C; Boucher G; Spinella JF; Boivin I; D'Angelo G; Lavallée S; Marinier A; Lemieux S; Hébert J; Sauvageau G
Leukemia; 2020 Jan; 34(1):63-74. PubMed ID: 31300747
[TBL] [Abstract][Full Text] [Related]
2. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
[TBL] [Abstract][Full Text] [Related]
4. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
[No Abstract] [Full Text] [Related]
7. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Chan SM; Thomas D; Corces-Zimmerman MR; Xavy S; Rastogi S; Hong WJ; Zhao F; Medeiros BC; Tyvoll DA; Majeti R
Nat Med; 2015 Feb; 21(2):178-84. PubMed ID: 25599133
[TBL] [Abstract][Full Text] [Related]
8. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
9. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
[TBL] [Abstract][Full Text] [Related]
10. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
Wang Q; Wan J; Zhang W; Hao S
Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.
Yu N; Seedhouse C; Russell N; Pallis M
Leuk Lymphoma; 2018 Oct; 59(10):2447-2453. PubMed ID: 29431553
[TBL] [Abstract][Full Text] [Related]
12. Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
Lin KH; Winter PS; Xie A; Roth C; Martz CA; Stein EM; Anderson GR; Tingley JP; Wood KC
Sci Rep; 2016 Jun; 6():27696. PubMed ID: 27283158
[TBL] [Abstract][Full Text] [Related]
13. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Niu X; Zhao J; Ma J; Xie C; Edwards H; Wang G; Caldwell JT; Xiang S; Zhang X; Chu R; Wang ZJ; Lin H; Taub JW; Ge Y
Clin Cancer Res; 2016 Sep; 22(17):4440-51. PubMed ID: 27103402
[TBL] [Abstract][Full Text] [Related]
14. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
15. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
16. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.
Pronier E; Levine RL
Cancer Cell; 2015 Mar; 27(3):323-5. PubMed ID: 25759018
[TBL] [Abstract][Full Text] [Related]
17. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
[TBL] [Abstract][Full Text] [Related]
18. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
19. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
20. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]